Related Experiment Video
Updated: Jul 4, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Review of tenofovir-emtricitabine
Saba Woldemichael Masho1, Cun-Lin Wang, Daniel E Nixon
1Department of Epidemiology and Community Health, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA. swmasho@vcu.edu
Abstract:
Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality. Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplified dosing convenience are being utilized. Tenofovir-emtricitabine (TDF-FTC) represents one of the more recent fixed-dose combinations. In combination with either a ritonavir-boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in recent treatment guidelines on the basis of demonstrated potency in randomized clinical trials, one-pill-a-day dosing convenience, and relatively low toxicity. In addition, the drug is active against hepatitis B virus. Caution must be exercised in patients with renal insufficiency, or when the drug is used with certain other drugs. This manuscript reviews the use of TDF-FTC in the treatment of HIV.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retroviruses
Subviral Agents
Inhibitors of Viral Protein Synthesis
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Antiprotozoal Agents
